Logo image of QGEN

QIAGEN N.V. (QGEN) Stock Price, Quote, News and Overview

NYSE:QGEN - New York Stock Exchange, Inc. - NL0015002CX3 - Common Stock - Currency: USD

39.57  +1 (+2.59%)

After market: 39.57 0 (0%)

QGEN Quote, Performance and Key Statistics

QIAGEN N.V.

NYSE:QGEN (2/21/2025, 8:04:00 PM)

After market: 39.57 0 (0%)

39.57

+1 (+2.59%)

Sector
GICS SectorHealth Care
GICS IndustryLife Sciences Tools & Services
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryLife Sciences Tools & Services
Statistics
52 Week High47.93
52 Week Low38.49
Market Cap8.55B
Shares216.08M
Float211.24M
Yearly DividendN/A
Dividend YieldN/A
PE18.07
Fwd PE16.86
Earnings (Next)04-30 2025-04-30/amc
IPO09-01 1996-09-01


QGEN short term performance overview.The bars show the price performance of QGEN in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months -5 -10

QGEN long term performance overview.The bars show the price performance of QGEN in the last 1, 2 and 3 years. 1 year 2 years 3 years -5 -10 -15 -20

The current stock price of QGEN is 39.57 USD. In the past month the price decreased by -13.66%. In the past year, price decreased by -9.7%.

QIAGEN N.V. / QGEN Daily stock chart

QGEN Competitors/Peers

The largest stocks on the US markets in the "Life Sciences Tools & Services" sub-industry
Full List
Symbol
Name
TA
FA
PE
Market Cap
TMO THERMO FISHER SCIENTIFIC INC 24.36 203.70B
DHR DANAHER CORP 28.07 151.18B
A AGILENT TECHNOLOGIES INC 25.59 38.62B
IQV IQVIA HOLDINGS INC 17.15 33.64B
MTD METTLER-TOLEDO INTERNATIONAL 31.26 26.91B
WAT WATERS CORP 31.58 22.26B
ICLR ICON PLC 14.39 16.63B
WST WEST PHARMACEUTICAL SERVICES 31.25 15.27B
ILMN ILLUMINA INC 38.45 14.94B
RVTY REVVITY INC 23.23 13.85B
AVTR AVANTOR INC 17.3 11.78B
TEM TEMPUS AI INC N/A 10.72B

About QGEN

Company Profile

QGEN logo image QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company is headquartered in Venlo, Limburg and currently employs 5,967 full-time employees. The firm is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials. Its assay technologies make these biomolecules visible for analysis, such as identifying the genetic information of a pathogen or a gene mutation in a tumor. Its bioinformatics solutions interpret data to provide actionable insights. The firm's automation platforms based on polymerase chain reaction (PCR), next-generation sequencing (NGS) and other technologies tie these together in molecular testing workflows from Sample to Insight.

Company Info

QIAGEN N.V.

Hulsterweg 82

Venlo LIMBURG 5912 NL

CEO: Thierry Bernard

Employees: 5900

Company Website: https://www.qiagen.com/

Investor Relations: https://corporate.qiagen.com/investor-relations/overview

Phone: 31773556600

QIAGEN N.V. / QGEN FAQ

What is the stock price of QIAGEN N.V. today?

The current stock price of QGEN is 39.57 USD. The price increased by 2.59% in the last trading session.


What is the ticker symbol for QIAGEN N.V. stock?

The exchange symbol of QIAGEN N.V. is QGEN and it is listed on the New York Stock Exchange, Inc. exchange.


On which exchange is QGEN stock listed?

QGEN stock is listed on the New York Stock Exchange, Inc. exchange.


What is the price forecast or stock price prediction for QIAGEN N.V. stock?

22 analysts have analysed QGEN and the average price target is 51.88 USD. This implies a price increase of 31.1% is expected in the next year compared to the current price of 39.57. Check the QIAGEN N.V. stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is QIAGEN N.V. worth?

QIAGEN N.V. (QGEN) has a market capitalization of 8.55B USD. This makes QGEN a Mid Cap stock.


How many employees does QIAGEN N.V. have?

QIAGEN N.V. (QGEN) currently has 5900 employees.


What are the support and resistance levels for QIAGEN N.V. (QGEN) stock?

QIAGEN N.V. (QGEN) has a support level at 39.56 and a resistance level at 39.58. Check the full technical report for a detailed analysis of QGEN support and resistance levels.


Is QIAGEN N.V. (QGEN) expected to grow?

The Revenue of QIAGEN N.V. (QGEN) is expected to grow by 5.1% in the next year. Check the estimates tab for more information on the QGEN EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy QIAGEN N.V. (QGEN) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does QIAGEN N.V. (QGEN) stock pay dividends?

QGEN does not pay a dividend.


When does QIAGEN N.V. (QGEN) report earnings?

QIAGEN N.V. (QGEN) will report earnings on 2025-04-30, after the market close.


What is the Price/Earnings (PE) ratio of QIAGEN N.V. (QGEN)?

The PE ratio for QIAGEN N.V. (QGEN) is 18.07. This is based on the reported non-GAAP earnings per share of 2.19 and the current share price of 39.57 USD. Check the full fundamental report for a full analysis of the valuation metrics for QGEN.


What is the Short Interest ratio of QIAGEN N.V. (QGEN) stock?

The outstanding short interest for QIAGEN N.V. (QGEN) is 1.21% of its float. Check the ownership tab for more information on the QGEN short interest.


QGEN Technical Analysis


Chartmill TA Rating
Chartmill Setup Rating

QGEN Fundamental Analysis

ChartMill assigns a fundamental rating of 6 / 10 to QGEN. QGEN has an excellent financial health rating, but there are some minor concerns on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

QGEN Financial Highlights

Over the last trailing twelve months QGEN reported a non-GAAP Earnings per Share(EPS) of 2.19. The EPS increased by 3.45% compared to the year before.


Industry RankSector Rank
PM (TTM) 4.23%
ROA 1.47%
ROE 2.34%
Debt/Equity 0.38
Chartmill High Growth Momentum
EPS Q2Q%10.91%
Sales Q2Q%2.36%
EPS 1Y (TTM)3.45%
Revenue 1Y (TTM)0.66%

QGEN Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 78% to QGEN. The Buy consensus is the average rating of analysts ratings from 22 analysts.

For the next year, analysts expect an EPS growth of 7.19% and a revenue growth 5.1% for QGEN


Ownership
Inst Owners87.54%
Ins Owners0.41%
Short Float %1.21%
Short Ratio2.28
Analysts
Analysts78.18
Price Target51.88 (31.11%)
EPS Next Y7.19%
Revenue Next Year5.1%